A phase II study of monalizumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): Results of the I1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)

Philip Debruyne

A phase II study of monalizumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): Results of the I1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)

School of Nursing and Midwifery

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Annals of Oncology
Publication status	Published - 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{05a4fc56d5224d8796fe8c2445b5d6f7,

title = "A phase II study of monalizumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): Results of the I1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)",

author = "Philip Debruyne",

year = "2019",

language = "English",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

}